{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:05Z","timestamp":1785551765639,"version":"3.56.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Tolvaptan (TVP) is an effective treatment for patients with cirrhotic ascites; however, studies have indicated that a sufficient effect is difficult to obtain in patients with hepatocellular carcinoma (HCC). This study evaluates the efficacy of TVP in patients with HCC with refractory ascites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively enrolled 32 patients with liver cirrhosis and refractory ascites [mean age: 74 years (range, 47\u201386 years), men: 78.1% (25\/32)]. All patients had HCC and were treated with TVP at our hospital. A TVP responder was defined as a patient who experienced decrease in body weight by \u22651.5 kg within 1 week of treatment. Univariate and multivariate analyses were performed to evaluate clinical and laboratory predictive factors of TVP response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The TVP response rate was 46.9% (15\/32 patients) after 1 week of treatment. HCC treatment (transcatheter arterial chemoembolization and\/or radiofrequency ablation) was administered to 11\/15 (73.3%) responders. In the multivariate analysis, the reduction of urine osmolality was higher in responders than nonresponders (202 mOsm\/l vs. 65 mOsm\/l, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.040), and the tumor stage (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.043) was worse in nonresponders. Multivariate Cox proportional hazards regression analysis indicated a significantly better prognosis among responders than among nonresponders (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The HCC tumor stage and the reduction in urine osmolality can predict the efficacy of TVP in patients with refractory ascites complicated with HCC. TVP may allow therapeutic intervention for HCC and improve prognosis, even in patients with Child\u2013Pugh class C.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000001985","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T04:15:47Z","timestamp":1605586547000},"page":"e161-e166","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma"],"prefix":"10.1097","volume":"33","author":[{"given":"Michitaka","family":"Imai","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Azumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terasu","family":"Honma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Management of cirrhosis and ascites.","volume":"350","author":"Gin\u00e8s","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012.","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1872-034X.2012.01012.x","article-title":"Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome.","volume":"42","author":"Takaki","year":"2012","journal-title":"Hepatol Res"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/hepr.12195","article-title":"Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites.","volume":"44","author":"Taki","year":"2014","journal-title":"Hepatol Res"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/1744-9987.12469","article-title":"Cell-Free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis.","volume":"20","author":"Kozaki","year":"2016","journal-title":"Ther Apher Dial"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2169\/internalmedicine.0629-17","article-title":"Association between the serum sodium levels and the response to tolvaptan in liver cirrhosis patients with ascites and hyponatremia.","volume":"57","author":"Hayashi","year":"2018","journal-title":"Intern Med"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/gast.2001.21193","article-title":"Factors associated with poor health-related quality of life of patients with cirrhosis.","volume":"120","author":"Marchesini","year":"2001","journal-title":"Gastroenterology"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","article-title":"Natural history of patients hospitalized for management of cirrhotic ascites.","volume":"4","author":"Planas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: the vaptans.","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"R10-20240821","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0300060513480089","article-title":"Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.","volume":"41","author":"Sakaida","year":"2013","journal-title":"J Int Med Res"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4254\/wjh.v7.i12.1685","article-title":"Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.","volume":"7","author":"Ohki","year":"2015","journal-title":"World J Hepatol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/hepr.12822","article-title":"Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.","volume":"47","author":"Kogiso","year":"2017","journal-title":"Hepatol Res"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1111\/hepr.12716","article-title":"Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites.","volume":"47","author":"Uojima","year":"2017","journal-title":"Hepatol Res"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hepr.12826","article-title":"Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.","volume":"47","author":"Kawaratani","year":"2017","journal-title":"Hepatol Res"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000448828","article-title":"Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis.","volume":"34","author":"Chishina","year":"2016","journal-title":"Dig Dis"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.3748\/wjg.v23.i29.5379","article-title":"Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.","volume":"23","author":"Miyazaki","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00535-017-1366-6","article-title":"Response criteria of tolvaptan for the treatment of hepatic edema.","volume":"53","author":"Hiramine","year":"2018","journal-title":"J Gastroenterol"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R19-20240821","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3892\/br.2015.521","article-title":"Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.","volume":"3","author":"Miyaaki","year":"2015","journal-title":"Biomed Rep"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"e0174649","DOI":"10.1371\/journal.pone.0174649","article-title":"Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na\/K ratio.","volume":"12","author":"Komiyama","year":"2017","journal-title":"PLoS One"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/hepr.12778","article-title":"Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema.","volume":"47","author":"Hiramine","year":"2017","journal-title":"Hepatol Res"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol Res"},{"key":"R23-20240821","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/17474124.2014.903797","article-title":"Tolvaptan for the treatment of liver cirrhosis oedema.","volume":"8","author":"Sakaida","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2015.","volume":"51","author":"Fukui","year":"2016","journal-title":"J Gastroenterol"},{"key":"R25-20240821","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2005.10.038","article-title":"Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure.","volume":"47","author":"Tsutamoto","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R26-20240821","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2169\/internalmedicine.55.6819","article-title":"Predictors of the effect of tolvaptan on the prognosis of cirrhosis.","volume":"55","author":"Iwamoto","year":"2016","journal-title":"Intern Med"},{"key":"R27-20240821","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R28-20240821","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/lt.20472","article-title":"Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.","volume":"11","author":"Pawlik","year":"2005","journal-title":"Liver Transpl"},{"key":"R29-20240821","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1007\/s13277-015-3311-8","article-title":"Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour Biol"},{"key":"R30-20240821","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3748\/wjg.v22.i21.5104","article-title":"Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.","volume":"22","author":"Nakagawa","year":"2016","journal-title":"World J Gastroenterol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000001985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:05:17Z","timestamp":1724364317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":30,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000001985","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}